JNJ 54175446

Drug Profile

JNJ 54175446

Alternative Names: JNJ-54175446

Latest Information Update: 13 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Janssen-Cilag
  • Class Antidepressants; Azoles; Phenols; Pyridines; Pyrimidines
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Major depressive disorder

Most Recent Events

  • 02 Jun 2017 Janssen Research & Development completes a phase I trial in Major depressive disorder in Germany and the Netherlands (PO) (NCT02902601)
  • 15 May 2017 Janssen completes a phase I trial in Major depressive disorder (In volunteers) in Belgium (PO) (NCT03058419)
  • 21 Apr 2017 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top